Cytomed Therapeutics Limited (GDTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | |
| Assets | |||
| Current Assets | |||
| Cash & Cash Equivalents | 3,638 | 6,818 | 1,179 |
| Receivables | 754 | 835 | 682 |
| TOTAL | $4,392 | $7,653 | $1,861 |
| Non-Current Assets | |||
| PPE Net | 2,381 | 1,565 | 1,846 |
| Investments And Advances | 162 | 148 | 179 |
| Intangibles | 68 | 9 | 14 |
| Other Non-Current Assets | 366 | 0 | 0 |
| TOTAL | $2,977 | $1,722 | $2,039 |
| Total Assets | $7,369 | $9,375 | $3,900 |
| Liabilities | |||
| Current Liabilities | |||
| Short Term Debt | 28 | 26 | 2,787 |
| Accounts payable and accrued liabilities | 323 | 398 | 311 |
| Other current liabilities | 88 | 115 | 3 |
| TOTAL | $444 | $543 | $3,107 |
| Non-Current Liabilities | |||
| Long Term Debt | 289 | 309 | 350 |
| Other Non-Current Liabilities | 4 | 0 | 0 |
| TOTAL | $306 | $309 | $355 |
| Total Liabilities | $750 | $853 | $3,462 |
| Shareholders' Equity | |||
| Common Shares | 17,416 | 17,979 | 6,650 |
| Retained earnings | -10,868 | -9,347 | -6,117 |
| Other shareholders' equity | 18 | -110 | -96 |
| TOTAL | $6,620 | $8,523 | $437 |
| Total Liabilities And Equity | $7,369 | $9,375 | $3,900 |